Background So far, investigators have found numerous tumor suppressor genes (TSGs) and oncogenes (OCGs) that control cell proliferation and apoptosis during cancer development. Furthermore, TSGs and OCGs may act as modulators of transcription factors (TFs) to influence gene regulation. A comprehensive investigation of TSGs, OCGs, TFs, and their joint target genes at the network level may provide a deeper understanding of the post-translational modulation of TSGs and OCGs to TF gene regulation. Methodology/Principal Findings In this study, we developed a novel computational framework for identifying target genes of TSGs and OCGs using TFs as bridges through the integration of protein-protein interactions and gene expression data. We applied this pipeline to ovarian cancer and constructed a three-layer regulatory network. In the network, the top layer was comprised of modulators (TSGs and OCGs), the middle layer included TFs, and the bottom layer contained target genes. Based on regulatory relationships in the network, we compiled TSG and OCG profiles and performed clustering analyses. Interestingly, we found TSGs and OCGs formed two distinct branches. The genes in the TSG branch were significantly enriched in DNA damage and repair, regulating macromolecule metabolism, cell cycle and apoptosis, while the genes in the OCG branch were significantly enriched in the ErbB signaling pathway. Remarkably, their specific targets showed a reversed functional enrichment in terms of apoptosis and the ErbB signaling pathway: the target genes regulated by OCGs only were enriched in anti-apoptosis and the target genes regulated by TSGs only were enriched in the ErbB signaling pathway. Conclusions/Significance This study provides the first comprehensive investigation of the interplay of TSGs and OCGs in a regulatory network modulated by TFs. Our application in ovarian cancer revealed distinct regulatory patterns of TSGs and OCGs, suggesting a competitive regulatory mechanism acting upon apoptosis and the ErbB signaling pathway through their specific target genes.
References
[1]
Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33 Suppl: 238–244
[2]
Sherr CJ (2004) Principles of tumor suppression. Cell 116: 235–246.
[3]
Croce CM (2008) Oncogenes and cancer. N Engl J Med 358: 502–511.
[4]
Klein G (2002) tumor suppressor genes: specific classes Encyclopedia of Cancer, Second Edition: 491–499.
[5]
Schwab M (1989) Genetic principles of tumor suppression. Biochim Biophys Acta 989: 49–64.
[6]
Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM (2009) A census of human transcription factors: function, expression and evolution. Nat Rev Genet 10: 252–263.
[7]
Everett L, Hansen M, Hannenhalli S (2010) Regulating the regulators: modulators of transcription factor activity. Methods Mol Biol 674: 297–312.
[8]
Park C, Lee I, Kang WK (2006) E2F-1 is a critical modulator of cellular senescence in human cancer. Int J Mol Med 17: 715–720.
[9]
Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, et al. (2008) Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27: 7094–7105.
[10]
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
[11]
Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415–428.
[12]
The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615.
[13]
Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, et al. (2011) Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One 6: e22469.
[14]
Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, et al. (2011) Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS One 6: e28141.
[15]
Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, et al. (2011) Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS One 6: e28503.
[16]
Riddick G, Fine HA (2011) Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 7: 439–450.
Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90: 1774–1786.
[19]
Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945–D950.
[20]
Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33: D514–517.
[21]
Becker KG, Barnes KC, Bright TJ, Wang SA (2004) The genetic association database. Nat Genet 36: 431–432.
[22]
Gong X, Wu R, Zhang Y, Zhao W, Cheng L, et al. (2010) Extracting consistent knowledge from highly inconsistent cancer gene data sources. BMC Bioinformatics 11: 76.
[23]
Kaur M, Radovanovic A, Essack M, Schaefer U, Maqungo M, et al. (2009) Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res 37: D820–823.
[24]
Aronson AR, Mork JG, Gay CW, Humphrey SM, Rogers WJ (2004) The NLM Indexing Initiative's Medical Text Indexer. Stud Health Technol Inform 107: 268–272.
[25]
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, et al. (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42: 880–884.
[26]
Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, et al. (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41: 996–1000.
[27]
Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42: 874–879.
[28]
Jia P, Kao CF, Kuo PH, Zhao Z (2011) A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Systems Biology 5 (Suppl 3): S12.
[29]
Sun J, Jia P, Fanous AH, Webb BT, van den Oord EJ, et al. (2009) A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case. Bioinformatics 25: 2595–2602.
[30]
Jia P, Sun J, Guo AY, Zhao Z (2010) SZGR: a comprehensive schizophrenia gene resource. Mol Psychiatry 15: 453–462.
[31]
Osborne C, Wilson P, Tripathy D (2004) Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9: 361–377.
[32]
Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, et al. (2003) MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31: 3576–3579.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177–183.
[35]
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498–2504.
R Development Core Team (2008) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3–900051–07–0, URL http://www.R-project.org.
[38]
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98–110.
[39]
Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, et al. (2009) Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27: 829–839.
[40]
Sun J, Gong X, Purow B, Zhao Z (2012) Uncovering microRNA and transcription factor mediated regulatory networks in glioblastoma. PLoS Comp Bio 8(7): e1002488.
[41]
Leung PC, Choi JH (2007) Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 13: 143–162.
[42]
Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, et al. (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76: 284–290.
[43]
Kvale G, Heuch I, Nilssen S, Beral V (1988) Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 42: 246–251.
[44]
Huang da W, Sherman BT, Tan Q, Collins JR, Alvord WG, et al. (2007) The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8: R183.
[45]
Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc B Met 57: 289–300.
[46]
Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, et al. (2011) ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 6: e17979.
[47]
Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, et al. (2011) Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat 129: 421–432.
[48]
Deng Y, Wu X (2000) Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci U S A 97: 12050–12055.
[49]
Tang MJ, Tai IT (2007) A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 282: 34457–34467.
[50]
Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, et al. (2007) RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 26: 683–700.
[51]
Abell K, Bilancio A, Clarkson RWE, Tiffen PG, Altaparmakov AI, et al. (2005) Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol 7: 392–398.
[52]
Konnikova L, Kotecki M, Kruger MM, Cochran BH (2003) Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3.
[53]
Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535–1542.
[54]
Xu DK, Wilson TJ, Chan D, De Luca E, Zhou J, et al. (2002) Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. EMBO J 21: 4081–4093.
[55]
Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, et al. (2010) Small molecule inhibitors of Wnt/beta-Catenin/Lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 12: 326–335.
[56]
Kim K, Pang KM, Evans M, Hay ED (2000) Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell 11: 3509–3523.
[57]
Huang Y, Lei YF, Zhang H, Zhang MJ, Dayton A (2011) Interleukin-12 treatment down-regulates STAT4 and induces apoptosis with increasing ROS production in human natural killer cells. J Leukocyte Biol 90: 87–97.
[58]
Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, et al. (2010) E2F3 Is a Mediator of DNA Damage-Induced Apoptosis. Mol Cell Biol 30: 524–536.
[59]
Hartman MG, Lu D, Kim ML, Kociba GJ, Shukri T, et al. (2004) Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol 24: 5721–5732.
[60]
Malek A, Bakhidze E, Noske A, Sers C, Aigner A, et al. (2008) HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123: 348–356.
[61]
Beleza-Meireles A, Tohonen V, Soderhall C, Schwentner C, Radmayr C, et al. (2008) Activating transcription factor 3: a hormone responsive gene in the etiology of hypospadias. Eur J Endocrinol 158: 729–739.
[62]
Parisi T, Yuan TL, Faust AM, Caron AM, Bronson R, et al. (2007) Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues. Mol Cell Biol 27: 2283–2293.
[63]
Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, et al. (2002) Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 21: 3190–3198.
[64]
Hunter DS, Klotzbucher M, Kugoh H, Cai SL, Mullen JP, et al. (2002) Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function. Cancer Res 62: 3766–3772.
[65]
Holmes KA, Song JS, Liu XLS, Brown M, Carroll JS (2008) Nkx3–1 and LEF-1 function as transcriptional inhibitors of estrogen receptor activity. Cancer Res 68: 7380–7385.
[66]
Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, et al. (1998) STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J 17: 6670–6677.
[67]
Lu D, Wolfgang CD, Hai T (2006) Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281: 10473–10481.
[68]
Shimada M, Nakadai T, Tamura TA (2003) TATA-binding protein-like protein (TLP/TRF2/TLF) negatively regulates cell cycle progression and is required for the stress-mediated G(2) checkpoint. Mol Cell Biol 23: 4107–4120.
[69]
Teng CB, Diao HL, Ma H, Cong J, Yu H, et al. (2004) Signal transducer and activator of transcription 3 (Stat3) expression and activation in rat uterus during early pregnancy. Reproduction 128: 197–205.
[70]
Sun JY, Hoshino H, Takaku K, Nakajima O, Muto A, et al. (2002) Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 21: 5216–5224.
[71]
Shelton DN, Goodheart MJ (2011) Wnt/β-catenin/Lef-1 signaling in the uterus and its implications in uterine gland formation and cancer development. Proc in Obst Gyn 2: 16.
[72]
Rebbeck TR, Spitz M, Wu X (2004) Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5: 589–597.
[73]
Santos SDM, Ferrell JE (2008) Systems biology - On the cell cycle and its switches. Nature 454: 288–289.
[74]
Dwyer J, Li H, Xu D, Liu JP (2007) Transcriptional regulation of telomerase activity: roles of the the Ets transcription factor family. Ann N Y Acad Sci 1114: 36–47.
[75]
Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I (2002) c-Ets1 is a promising marker in epithelial ovarian cancer. Int J Mol Med 9: 287–292.
[76]
Mahajan A, Liu ZJ, Gellert L, Zou XY, Yang GY, et al. (2010) HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 23: 673–681.
